Compare CSX Corporation (CSX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Inovio Pharmaceuticals Inc — how do they compare? CSX Corporation trades at $47.3 (market cap $87.70B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: CSX Corporation is far larger — about 781.7× Inovio Pharmaceuticals Inc's market cap, and CSX Corporation pays a 1.18% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| CSX | INO | |
|---|---|---|
Market Cap | $87.70B | $112.19M |
Volume | 6,980,781 | 3,201,278 |
Sector | Industrials | Health |
52-Week High | $53.21 | $2.65 |
52-Week Low | $33.68 | $0.66 |
Typical Hold Time | 55 Days | 43 Days |
Enterprise Value | $105.66B | $83.51M |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.26, up 0.96% with a bullish technical signal. The stock shows strong profitability with 22.21% net margin and 24.37% ROE, though revenue declined to $14.09B in 2025. Recent Q2 2026 earnings beat expectations at $0.54 vs $0.518. Analyst consensus is bullish with 58.69% buy ratings and $51.00 price target. The company maintains stable cash flow operations and recently announced a $0.14 dividend payable September 2026.
CSX presents a favorable investment case with strong fundamentals and analyst support, though valuation metrics appear elevated. Key risks include revenue pressure and competitive threats. The upcoming Q3 2026 earnings on October 21 will be critical for confirming the positive trend. Current levels offer potential upside to consensus targets but require monitoring of operational execution.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
